[Federal Register Volume 70, Number 163 (Wednesday, August 24, 2005)]
[Notices]
[Pages 49622-49623]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 05-16367]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

[30Day-05-03AA]


Proposed Data Collections Submitted for Public Comment and 
Recommendations

    The Centers for Disease Control and Prevention (CDC) publishes a 
list of information collection requests under review by the Office of 
Management and Budget (OMB) in compliance with the Paperwork Reduction 
Act (44 U.S.C. Chapter 35). To request a copy of these requests, call 
the CDC Reports Clearance Officer at (404) 371-5983 or send an e-mail 
to [email protected]. Send written comments to CDC Desk Officer, Human 
Resources and Housing Branch, New Executive Office Building, Room 
10235, Washington, DC 20503 or by fax to (202) 395-6974. Written 
comments should be received within 30 days of this notice.

Proposed Project

    Potential Reproductive and Neurological Effects of Exposure to 
Acrylamide--NEW--The National Institute for Occupational Safety and 
Health (NIOSH), Centers for Disease Control and Prevention (CDC).
    The mission of the National Institute for Occupational Safety and 
Health (NIOSH) is to promote safety and health at work for all people 
through research and prevention. Consistent with this mission, NIOSH is 
undertaking a study of the reproductive and neurobehavioral effects of 
occupational exposure to acrylamide. Male acrylamide workers and 
control workers (N = 100 per group) will be recruited from 
manufacturing, end-user, and non-exposed settings. Exposure will be 
characterized by acrylamide hemoglobin, adduct and urinary metabolite 
levels, ambient area, personal air, and dermal sampling. Reproductive 
effects will be evaluated by examining semen quality, sperm DNA 
integrity, reproductive hormone levels, and prostate specific antigen 
(PSA) levels.
    Neurobehavioral effects will be assessed using sensation-tactile, 
postural stability, grooved pegboard, and simple reaction time tests. 
Two questionnaires will be administered on one occasion. Questionnaire 
information will be collected concurrently to augment test 
interpretation, adjust for potential confounders and covariates during 
regression analysis, correlate specific jobs and job activities with 
exposure measurements, and for validation purposes. Findings from this 
study will clarify if the adverse reproductive effects observed in 
animal studies are also present in acrylamide-exposed male workers, and 
if preclinical neurobehavioral deficits are present at acrylamide doses 
currently considered to be within safe limits. This study is scheduled 
for implementation between 2005 and 2007. There is no cost to the 
respondent other than their time for participating. The annualized 
estimated burden for this data collection is 54 hours.

                                       Estimate of Annualized Burden Table
----------------------------------------------------------------------------------------------------------------
                                                                                                      Average
                                                                     Number of       Number of        burden/
                      Survey questionnaires                         respondents     responses/       response
                                                                                    respondent        (hours)
----------------------------------------------------------------------------------------------------------------
Medical & Reproductive History Questionnaire....................              67               1           13/60
Occupational History Questionnaire..............................              67               1           34/60
Non-participant Questionnaire...................................              17               1            2/60
----------------------------------------------------------------------------------------------------------------



[[Page 49623]]

    Dated: August 11, 2005.
Joan F. Karr,
Acting Reports Clearance Officer, Centers for Disease Control and 
Prevention.
[FR Doc. 05-16367 Filed 8-23-05; 8:45 am]
BILLING CODE 4163-18-P